Allergan, Inc.

Allergan Sales, Inc.

June Chen

David Frederick Woodward

Simon Neil Pettit

Hans G Fliri

Alexander B Kharlamb

Robert M Burk

Rhett M Schiffman

Achim H-p Krauss

Michael E Garst

David W Old

Steven Wade Andrews

Larry Allen Wheeler

Yariv Donde

Mark Holoboski

Yanbin Liang

Cherukury Madhu

Helen H Usansky

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

Hypotensive lipid and timolol compositions and methods of using same

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists.

Cannabinoid-2 agonists

Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.

Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists. (Formula I and III) 

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.

Abnormal cannabidiols as agents for lowering intraocular pressure

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.

The present invention relates to novel EP2 Receptor agonists that are useful for treating glaucoma and other conditions and indications in man. Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.

Growing community of inventors

San Juan Capistrano, CA, United States of America

June Chen